ZBH

Prezzo Zimmer Biomet Holdings Inc

Closed
ZBH
$83,29
+$0,29(+0,34%)

*Data last updated: 2026-05-10 11:09 (UTC+8)

As of 2026-05-10 11:09, Zimmer Biomet Holdings Inc (ZBH) is priced at $83,29, with a total market cap of $15,92B, a P/E ratio of 25,24, and a dividend yield of 1,16%. Today, the stock price fluctuated between $82,00 and $84,50. The current price is 1,57% above the day's low and 1,43% below the day's high, with a trading volume of 1,72M. Over the past 52 weeks, ZBH has traded between $79,78 to $94,08, and the current price is -11,46% away from the 52-week high.

ZBH Key Stats

Yesterday's Close$83,37
Market Cap$15,92B
Volume1,72M
P/E Ratio25,24
Dividend Yield (TTM)1,16%
Dividend Amount$0,24
Diluted EPS (TTM)3,90
Net Income (FY)$705,20M
Revenue (FY)$8,23B
Earnings Date2026-08-06
EPS Estimate2,01
Revenue Estimate$2,13B
Shares Outstanding191,04M
Beta (1Y)0.473
Ex-Dividend Date2026-03-31
Dividend Payment Date2026-04-30

About ZBH

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
SectorHealthcare
IndustryMedical - Devices
CEOIvan Tornos
HeadquartersWarsaw,IN,US
Employees (FY)17,00K
Average Revenue (1Y)$484,20K
Net Income per Employee$41,48K

Zimmer Biomet Holdings Inc (ZBH) FAQ

What's the stock price of Zimmer Biomet Holdings Inc (ZBH) today?

x
Zimmer Biomet Holdings Inc (ZBH) is currently trading at $83,29, with a 24h change of +0,34%. The 52-week trading range is $79,78–$94,08.

What are the 52-week high and low prices for Zimmer Biomet Holdings Inc (ZBH)?

x

What is the price-to-earnings (P/E) ratio of Zimmer Biomet Holdings Inc (ZBH)? What does it indicate?

x

What is the market cap of Zimmer Biomet Holdings Inc (ZBH)?

x

What is the most recent quarterly earnings per share (EPS) for Zimmer Biomet Holdings Inc (ZBH)?

x

Should you buy or sell Zimmer Biomet Holdings Inc (ZBH) now?

x

What factors can affect the stock price of Zimmer Biomet Holdings Inc (ZBH)?

x

How to buy Zimmer Biomet Holdings Inc (ZBH) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

Hot Posts su Zimmer Biomet Holdings Inc (ZBH)

SelfRugger

SelfRugger

05-07 14:31
3 Reasons to Avoid ZBH and 1 Stock to Buy Instead ================================================= 3 Reasons to Avoid ZBH and 1 Stock to Buy Instead Petr Huřťák Thu, February 19, 2026 at 1:01 PM GMT+9 3 min read In this article: ZBH -0.27% ^GSPC -0.34% Over the last six months, Zimmer Biomet’s shares have sunk to $98.28, producing a disappointing 5.8% loss - a stark contrast to the S&P 500’s 6.7% gain. This may have investors wondering how to approach the situation. Is now the time to buy Zimmer Biomet, or should you be careful about including it in your portfolio? See what our analysts have to say in our full research report, it’s free. Why Is Zimmer Biomet Not Exciting? ---------------------------------- Despite the more favorable entry price, we're cautious about Zimmer Biomet. Here are three reasons why ZBH doesn't excite us and a stock we'd rather own. ### 1. Long-Term Revenue Growth Disappoints Reviewing a company’s long-term sales performance reveals insights into its quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Over the last five years, Zimmer Biomet grew its sales at a mediocre 5.3% compounded annual growth rate. This was below our standard for the healthcare sector. Zimmer Biomet Quarterly Revenue ### 2. Projected Revenue Growth Is Slim Forecasted revenues by Wall Street analysts signal a company’s potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite. Over the next 12 months, sell-side analysts expect Zimmer Biomet’s revenue to rise by 3.8%, a slight deceleration versus its 5.3% annualized growth for the past five years. This projection is underwhelming and suggests its products and services will face some demand challenges. ### 3. Previous Growth Initiatives Haven’t Impressed Growth gives us insight into a company’s long-term potential, but how capital-efficient was that growth? A company’s ROIC explains this by showing how much operating profit it makes compared to the money it has raised (debt and equity). Zimmer Biomet historically did a mediocre job investing in profitable growth initiatives. Its five-year average ROIC was 4.1%, lower than the typical cost of capital (how much it costs to raise money) for healthcare companies. Zimmer Biomet Trailing 12-Month Return On Invested Capital Final Judgment -------------- Zimmer Biomet isn’t a terrible business, but it doesn’t pass our bar. Following the recent decline, the stock trades at 11.6× forward P/E (or $98.28 per share). This valuation is reasonable, but the company’s shakier fundamentals present too much downside risk. We're pretty confident there are more exciting stocks to buy at the moment. We’d recommend looking at one of our top digital advertising picks. High-Quality Stocks for All Market Conditions --------------------------------------------- The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 5 Growth Stocks for this month. This is a curated list of our _High Quality_ stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025). Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. Terms and Privacy Policy Privacy Dashboard More Info
0
0
0
0